Specialty pharmacy dynamics
The SP channel continues to grow, with manufacturers looking for more control over access
Pharma gets into the 'digital workflow' of physicians
Given the accelerating growth of electronic health record (EHR) adoption, pharma marketers are hoping for a new communication channel to open up at the point of care in the physician's office
Biomarkers create opportunities, complicate drug dispensing
The healthcare system is coming to grips with the wave of genomic diagnostics that has followed new biological therapy introductions
Navigating the tense, complex oncology market
Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension
Generics Manufacturers Grapple With Tight Economics
But the global picture is sunny as most of the global market growth benefits the generic makers
THE ONGOING DIABETES BATTLEGROUND
Even as diagnosed (and “prediabetes”) cases rise worldwide, healthcare providers struggle with patients to control the course of the disease. New therapies—and new health services—are aiding in the battle
Aggregate Spend Laws: Here Comes the Sun
The industry is far from ready when it comes to collecting, aggregating, cleansing and disclosing data about regulated financial transactions with doctors and hospitals
With a Few Stumbles, REMS Begins to Hit Its Stride
Nearly 200 drugs now carry requirements for a risk management program, as FDA evaluates the initial follow-up reporting from manufacturers
The Changing Face of Today's PAPs
Once reserved for uninsured, many patient-assistance programs have evolved to meet the needs of the under-insured. On the horizon: the potential effects of healthcare reform law
The Struggle to Get Anti-Infectives on a Faster Track to Commercialization
A looming crisis in drug-resistant anti-infectives is not being met with a commensurate industry effort. Governments and industry are trying to cope
Rare Diseases and Orphan Drugs Lift Pharma Innovation
As hundreds of candidate drugs receive official “orphan” status, the Orphan Drug Act gets re-examined. Meanwhile, these drugs are driving the growth of specialty pharmacy
Reverse Logistics Providers Upgrade Their Service Capabilities
Even while cutting the costs of recalls and returns, providers offer new marketing tools to industry
Surprise! Employment Is on the Rise--in Contract Sales
While staff sales forces continue to shrink, the contract sales business is expected to nearly double over the next five years
50 Years of Birth Control: Pharma Continues to Push for More Reproductive-Health Options
The Pill as OTC -- Access Versus Health Concerns
Some healthcare providers are pushing for OTC access to birth control. Pharma appears to be on the sideline in the debate
Improving Outcomes Research Protocols
Patient Outcomes Research Moves Drug Development Beyond Clinical Results
Industry Tackles the New REMS Hurdle
FDA’s requirements for risk evaluation and mitigation challenge both new and existing commercialization processes
Botox Lawsuit Highlights Another Wrinkle for REMS
The current FDA policy toward REMS is being challenged by Allergan
PHRMA, Foundations Establish 'Medical Homes' in New Jersey
Program seeks to improve the economics of care for low-income families; more sites to come
Putting Nursing Into the Pharmaceutical Usage Equation
While nurses move into a more central role in prescribing and administering pharmaceuticals, the nursing professions debate industry influence
Home-Infusion Providers Struggle With Unfriendly Reimbursement Policies
PHRMA, foundations establish 'medical homes' in New Jersey
Surveying the Mental Health Medication Landscape--Part 2
Central nervous system (CNS) medication for society’s oldest and youngest present special challenges
Surveying the Mental Health Medication Landscape - Part 1
Antipsychotic and antidepressant drugs have risen to the top categories of prescribed medications in a challenging and risky medical and regulatory arena
A Pitched Battle in Cardiovascular Drug Marketing
Mature product franchises and mixed clinical outcomes have not dissuaded pharma companies from expending marketing resources for cardiovascular disease treatment